Furthermore, we show that early somatic POLE mutations are likely to cause an enrichment of clonal neoantigens that may explain the goodprognosis of cancers carrrying these variants, and their excellent response to immune checkpoint inhibitors. This evidence concerns the gene POLE and cancer.